FDA accepts Otonomy’s NDA for AuriPro to treat middle ear effusion in pediatric patients
The acceptance of the NDA indicates the application is sufficiently complete to permit a substantive review by the FDA. "The FDA’s acceptance of our NDA filing brings us
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.